OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance
ORTHOPEDIATRICS CORP (KIDS) filed an SEC Form 8-K — Results of Operations and Financial Condition. OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance Second Quarter 2026 Revenue Surpasses $70 million for the First Time in Company History, and Increased 15% Year-over-Year WARSAW, Ind., August 4, 2026 -- OrthoPediatrics Corp
How this was made
The 30-second read
Why it matters
The newest actionable information is the raised FY 2026 revenue guidance range and the reaffirmed expectation for adjusted EBITDA and free-cash-flow breakeven in 2026, alongside record Q2 adjusted EBITDA and improved free-cash-flow usage.
Market read
For KIDS, the filing provides a fresh guidance update and multiple Q2 performance datapoints (revenue, adjusted EBITDA, free cash flow usage) that can drive near-term sentiment and valuation adjustments.
What to watch
Cash and investments fell to $47.9M from $62.9M at year-end, and the company still posted a $7.2M net loss in Q2; traders may focus on whether free-cash-flow improvement is sustainable beyond working-capital effects.
Background
This is an SEC Form 8-K (Item 2.02) with the company’s Q2 2026 results and updated full-year 2026 guidance, plus business highlights and financial statement highlights.
Ticker impact
OrthoPediatrics (KIDS) reported Q2 revenue of $70.5M, raised 2026 revenue guidance to $265.0M-$269.0M, and reiterated 2026 EBITDA and free-cash-flow breakeven expectations.
Near-term upside bias as traders price higher 2026 revenue range and cash-flow breakeven credibility; magnitude depends on how the market values the guidance raise versus ongoing net losses.
The filing discloses multiple decision-relevant datapoints: Q2 revenue and adjusted EBITDA records, a specific full-year guidance raise, and a stated path to free-cash-flow breakeven in 2026. However, the company still reports a net loss and the excerpt does not include consensus comparisons or detailed segment margin drivers beyond high-level commentary.
Market effects
Reinforces demand and adoption momentum in pediatric orthopedics implants, potentially supporting sentiment for small-cap medtech peers with similar procedure-driven revenue models.
Limited direct regional read-through; international revenue grew 22% in the quarter, but no country-specific regulatory or reimbursement changes were disclosed.
Mostly company-specific; could marginally affect investor sentiment toward niche orthopedic implant manufacturers if the guidance raise is viewed as durable.
Counterpoint
Scoliosis revenue declined 9% in Q2 due to lower set sales and timing of capital placements, which could indicate uneven demand or execution risk despite overall growth.
Key entities
- issuerOrthoPediatrics Corp.
Nasdaq-listed pediatric orthopedics company reporting Q2 2026 results and increasing FY 2026 revenue guidance.
- partnerOSSIO, Inc.
Announced exclusive distribution agreement with OrthoPediatrics for U.S. children’s hospitals.
